Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Middlemen’ Markups Are Penalizing Patients, Says AAM

Cash Prices For Generic Drugs Are Substantially Higher Than Manufacturer Prices

Executive Summary

The Association for Accessible Medicines has launched its Markup Madness campaign, which seeks to draw attention to the disparity in cost between generic drugs upon entry to the supply chain and when purchased in pharmacies.

You may also be interested in...



AAM Challenges Minnesota Drug Price Law With Federal Injunction Request

Minnesota is the latest US state to find itself facing generic drug trade group the Association for Accessible Medicines in court, after the organization filed a lawsuit alleging that its new drug pricing legislation is unconstitutional.

PBM Vertical Integration Impact Under The Microscope At Senate Hearing

A US Senate Finance Committee has heard divided opinions on the impact of vertical integration among pharmacy benefit managers, with one witness maintaining it may have positive competitive consequences while another condemned the practice outright.

Celltrion CCO On The Big US Build-Up, Direct Sales Model

Celltrion USA’s chief commercial officer Thomas Nusbickel tells Scrip how he’s shaping the South Korean group’s operations ahead of key launches that include assets in the immunology segment. He also weighs in on whether big pharma will stay in the biosimilars game over the long term.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel